Uveal and conjunctival malignant melanoma in Denmark 1943-97: Observed and relative survival of patients followed through 2002

Ophthalmic Epidemiology

Volumn 13, Issue 2, 2006, Pages 85-96

  Isager, P ^a   Engholm, G ^b   Overgaard, J ^a   Storm, H ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Conjunctival melanoma; Danish cancer registry; Melanoma; Ocular tumors; Survival; Uveal melanoma

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHOROID MELANOMA; CILIARY BODY TUMOR; CONJUNCTIVA TUMOR; DENMARK; EYE TUMOR; FEMALE; HUMAN; INFANT; IRIS TUMOR; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; SURVIVAL; SURVIVAL RATE; UVEA MELANOMA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CONJUNCTIVAL NEOPLASMS; DENMARK; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; SURVIVAL RATE; TIME FACTORS; UVEAL NEOPLASMS;

EID: 33645648584     PISSN: 09286586     EISSN: 17445086     Source Type: Journal    
DOI: 10.1080/09286580600553330     Document Type: Article

References (51)

1. Isager P, Østerlind A, Engholm G, Heegaard S, Lindegaard J, Overgaard J, Storm HH. Malignant melanoma in the ocular region in Denmark 1943-97. Incidence and validation study. Ophthalmic Epidemiology 2005;12:223-232.
2. Seregard S. Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1,066 patients. Acta Ophthalmol Scand. 1999;77:414-417.
3. The Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma. COMS report no. 4. Arch Ophthalmol. 1997;115:886-893.
4. The Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119:969-982.
5. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992;110:245-250.
6. Seddon JM, Gragoudas ES, Egan KM, Glynn RJ, Howard S, Fante RG, Albert DM. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology 1990;97:769-777.
7. Castro JR, Char DH, Petti PL, Daftari IK, Quivey JM, Singh RP, Blakely EA, Phillips TL. 15 years experience with helium ion radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 1997;39:989-996.
8. The Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of preenucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2004;138:936-951.
9. Rones B, Zimmerman LE. The prognosis of primary tumors of the iris treated by iridectomy. Arch Ophthalmol. 1958;60:193-205.
10. Reese AB, Cleasby GW. The treatment of iris melanoma. Am J Ophthalmol. 1959;47:118-125.
11. Ashton N, Wybar K. Primary tumours of the iris. Ophthalmologica 1966;151:97-113.
12. Sunba MS, Rahi AH, Morgan G. Tumors of the anterior uvea. I. Metastasizing malignant melanoma of the iris. Arch Ophthalmol. 1980;98:82-85.
13. Geisse LJ, Robertson DM. Iris melanomas. Am J Ophthalmol. 1985;99:638-648.
14. Jensen OA. Malignant melanoma of the iris. A 25-year analysis of Danish cases. Eur J Ophthalmol. 1993;3:181-188.
15. Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD, Smith A. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology 2001;108:172-178.
16. Paridaens AD, Minassian DC, McCartney AC, Hungerford JL. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol. 1994;78:252-259.
17. Anastassiou G, Heiligenhaus A, Bechrakis N, Bader E, Bornfeld N, Steuhl KP. Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol. 2002;86:163-167.
18. Shields CL, Shields JA, Gunduz K, Cater J, Mercado GV, Gross N, Lally B. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000;118:1497-1507.
19. Werschnik C, Lommatzsch PK. Long-term follow-up of patients with conjunctival melanoma. Am J Clin Oncol. 2002;25:248-255.
20. Liesegang TJ, Campbell RJ. Mayo Clinic experience with conjunctival melanomas. Arch Ophthalmol. 1980;98:1385-1389.
21. de Wolff-Rouendaal D. Conjunctival Melanoma in the Netherlands: a clinico-pathological and follow-up study. Thesis, University of Leiden ed. Katwijk: All in BV, 1990.
22. Norregaard JC, Gerner N, Jensen OA, Prause JU. Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population. Graefes Arch Clin Exp Ophthalmol. 1996;234:569-572.
23. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003;110:962-965.
24. Raivio I. Uveal melanoma in Finland. Acta Ophthalmol (Copenh) 1977;Suppl 133 (thesis).
25. Isager P, Ehlers N, Overgaard J. Have choroidal and ciliary body melanomas changed during the period 1955-2000? Acta Ophthalmol Scand. 2004;82:509-516.
26. Jensen OA. Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943-1952. Acta Ophthalmol. (Copenh) 1982;60:161-182.
27. Bergman L, Seregard S, Nilsson B, Lundell G, Ringborg U, Ragnarsson-Olding B. Uveal melanoma survival in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci. 2003;44:3282-3287.
28. McGalliard JN, Johnston PB. A study of iris melanoma in Northern Ireland. Br J Ophthalmol. 1989;73:591-595.
29. Seregard S, Kock E. Conjunctival malignant melanoma in Sweden 1969-91. Acta Ophthalmol. (Copenh) 1992;70:289-296.
30. Conley J. Is melanoma changing? Otolaryngol Head Neck Surg. 1991;104:327-332.
31. Mansson-Brahme E, Johansson H, Larsson O, Rutqvist LE, Ringborg U. Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976-1994. Acta Oncol. 2002;41:138-146.
32. MacKie RM, Bray CA, Hole DJ, Morris A, Nicolson M, Evans A, Doherty V, Vestey J. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002;360:587-591.
33. Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol Scand 1995;73:340-344.
34. Kroll S, Char DH, Quivey J, Castro J. A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma. Ophthalmology 1998;105:2035-2045.
35. McLean IW, Ainbinder DJ, Gamel JW, McCurdy JB. Choroidal-ciliary body melanoma. A multivariate survival analysis of tumor location. Ophthalmology 1995;102:1060-1064.
36. Isager P, Ehlers N, Overgaard J. Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas. Acta Ophthalmol Scand 2004;82:517-525.
37. Demirci H, Shields CL, Shields JA, Eagle RC, Jr., Honavar SG. Diffuse iris melanoma: a report of 25 cases. Ophthalmology 2002;109:1553-1560.
38. Folberg R, McLean IW, Zimmerman LE. Malignant melanoma of the conjunctiva. Hum Pathol. 1985;16:136-143.
39. Augsburger JJ, Schneider S, Freire J, Brady LW. Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol 1999;237:558-567.
40. Woll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res. 1999;9:575-581.
41. World Health Organization. International Classification of Diseases for Oncology (ICD-O). First edition ed. Geneva: World Health Organization, 1976.
42. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, 1955. Seventh revision ed. Geneva: World Health Organization, 1957.
43. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982;38:933-942.
44. Therneau T, Sick J, Bergstralh E, Offors J. Expected survival on hazard rates. Technical Report no. 52. Rochester, Minnesota: MAYO Foundation, 1994.
45. Buch P. Befolkningsudvikling og Sundhedsforhold 1901-60. København: Det Statistiske Departement, Danmarks Statistik (Statistics Denmark), 1966:102.
46. Danmarks Statistik (Statistics Denmark). Befolkningens Bevægelser (Vital Statistics). Annual Publications: 1963-1982. 1963.
47. Statistics Denmark. www.statbank.dk. Internet. 2003.
48. Storm HH. Validitet af danske dødsattester for cancerpatienter 1977. København: 1984:1-66.
49. Augsburger JJ, Gamel JW. Clinical prognostic factors in patients with posterior uveal malignant melanoma. Cancer 1990;66:1596-1600.
50. Seregard S, Spangberg B, Juul C, Oskarsson M. Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma. Ophthalmology 1998;105:485-491.
51. Jakobiec FA, Silbert G. Are most iris "melanomas' really nevi? A clinicopathologic study of 189 lesions. Arch Ophthalmol 1981;99:2117-2132.